155 related articles for article (PubMed ID: 25979969)
21. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
22. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Lamar JM; Xiao Y; Norton E; Jiang ZG; Gerhard GM; Kooner S; Warren JSA; Hynes RO
J Biol Chem; 2019 Feb; 294(7):2302-2317. PubMed ID: 30559289
[TBL] [Abstract][Full Text] [Related]
23. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
[TBL] [Abstract][Full Text] [Related]
24. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
[TBL] [Abstract][Full Text] [Related]
25. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
[TBL] [Abstract][Full Text] [Related]
26. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
27. A Reciprocal Role of the Smad4-Taz Axis in Osteogenesis and Adipogenesis of Mesenchymal Stem Cells.
Park JS; Kim M; Song NJ; Kim JH; Seo D; Lee JH; Jung SM; Lee JY; Lee J; Lee YS; Park KW; Park SH
Stem Cells; 2019 Mar; 37(3):368-381. PubMed ID: 30444564
[TBL] [Abstract][Full Text] [Related]
28. The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members.
Mahoney WM; Hong JH; Yaffe MB; Farrance IK
Biochem J; 2005 May; 388(Pt 1):217-25. PubMed ID: 15628970
[TBL] [Abstract][Full Text] [Related]
29. The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner.
Shanzer M; Ricardo-Lax I; Keshet R; Reuven N; Shaul Y
Oncogene; 2015 Aug; 34(32):4190-8. PubMed ID: 25362852
[TBL] [Abstract][Full Text] [Related]
30. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
31. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
[TBL] [Abstract][Full Text] [Related]
32. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
33. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
34. A MYC-Driven Change in Mitochondrial Dynamics Limits YAP/TAZ Function in Mammary Epithelial Cells and Breast Cancer.
von Eyss B; Jaenicke LA; Kortlever RM; Royla N; Wiese KE; Letschert S; McDuffus LA; Sauer M; Rosenwald A; Evan GI; Kempa S; Eilers M
Cancer Cell; 2015 Dec; 28(6):743-757. PubMed ID: 26678338
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a novel compound that promotes myogenesis via Akt and transcriptional co-activator with PDZ-binding motif (TAZ) in mouse C2C12 cells.
Kodaka M; Mao F; Arimoto-Matsuzaki K; Kitamura M; Xu X; Yang Z; Nakagawa K; Maruyama J; Ishii K; Akazawa C; Oyaizu T; Yamamoto N; Ishigami-Yuasa M; Tsuemoto N; Ito S; Kagechika H; Nishina H; Hata Y
PLoS One; 2020; 15(4):e0231265. PubMed ID: 32267872
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ Fails to Separate Benign From Malignant Mesothelial Proliferations.
Sheffield BS; Lorette J; Shen Y; Marra MA; Churg A
Arch Pathol Lab Med; 2016 May; 140(5):391. PubMed ID: 27128293
[No Abstract] [Full Text] [Related]
37. Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation.
Oku Y; Nishiya N; Sugiyama S; Sato H; Uehara Y
Anticancer Res; 2018 Jun; 38(6):3471-3476. PubMed ID: 29848699
[TBL] [Abstract][Full Text] [Related]
38. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
[TBL] [Abstract][Full Text] [Related]
39. TAZ is required for the osteogenic and anti-adipogenic activities of kaempferol.
Byun MR; Jeong H; Bae SJ; Kim AR; Hwang ES; Hong JH
Bone; 2012 Jan; 50(1):364-72. PubMed ID: 22108137
[TBL] [Abstract][Full Text] [Related]
40. IRS-1 targets TAZ to inhibit adipogenesis of rat bone marrow mesenchymal stem cells through PI3K-Akt and MEK-ERK pathways.
Wang N; Li Y; Li Z; Ma J; Wu X; Pan R; Wang Y; Gao L; Bao X; Xue P
Eur J Pharmacol; 2019 Apr; 849():11-21. PubMed ID: 30716312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
